Your browser doesn't support javascript.
Acute Kidney Injury after First Dose of AstraZeneca COVID-19 Vaccine Managed in a Nigerian Hospital.
Onukak, A E; Akpan, E E; Udo, A I A; Kalu, M K.
  • Onukak AE; Department of Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria.
  • Akpan EE; Department of Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria.
  • Udo AIA; Department of Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria.
  • Kalu MK; Department of Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria.
West Afr J Med ; 39(7): 769-771, 2022 Jul 31.
Article in English | MEDLINE | ID: covidwho-1980941
ABSTRACT

INTRODUCTION:

The association of kidney disease and COVID-19 vaccination has been reported with minimal change disease being a common presentation. CASE REPORT Index patient is a 54-year-old female who presented with a history of reduction in urine output within 3 weeks of receiving the Oxford-AztraZeneca COVID-19 vaccine. Her serum creatinine on admission was 1,057 µmol/L with a premorbid serum creatinine of 78 µmol/L. Her vital signs were stable. She was on antihypertensive and antidiabetic medications for hypertension and diabetes mellitus, respectively. Renal biopsy was precluded by her morbid obesity and she was commenced on oral prednisolone. She had 5 sessions of hemodialysis and her serum creatinine gradually reduced to 106 µmol/L, and she is being followed up on an outpatient basis.

CONCLUSION:

We report a case of a female patient with acute kidney injury following COVID-19 Oxford-AztraZeneca vaccination. Further studies are required to better understand the pathogenesis of the renal affectation post-vaccination.

INTRODUCTION:

L'association de la maladie rénale et de la vaccination COVID-19 a été signalée, la maladie à changement minimal est une présentation courante. RAPPORT DE CAS La patiente à l'étude est une femme de 54 ans qui a présenté des antécédents de réduction du débit urinaire dans les 3 semaines après avoir reçu le vaccin COVID-19 d'Oxford-AztraZeneca. Sa créatinine sérique à l'admission était de 1 057 µmol/L avec une créatinine sérique prémorbide de 78 µmol/L. Ses signes vitaux étaient stables. Elle prenait des médicaments antihypertenseurs et antidiabétiques pour l'hypertension et le diabète sucré, respectivement. Une biopsie rénale était impossible à cause de son obésité morbide et elle a été mise sous prednisolone par voie orale. Elle a subi 5 sessions d'hémodialyse et son taux de créatinine sérique a progressivement à 106 µmol/L, et elle est suivie en ambulatoire.

CONCLUSION:

Nous rapportons le cas d'une patiente souffrant d'une lésion rénale aiguë après la vaccination par le COVID-19 Oxford-AztraZeneca. D'autres études sont nécessaires pour mieux comprendre la pathogenèse de l'affectation rénale post-vaccination. Mots-clés Vaccin COVID-19, Événement Indésirable, Lésion Rénale Aiguë.
Subject(s)
Keywords
Search on Google
Collection: International databases Database: MEDLINE Main subject: Acute Kidney Injury / COVID-19 / ChAdOx1 nCoV-19 Type of study: Case report / Observational study / Prognostic study Topics: Vaccines Limits: Female / Humans / Middle aged Country/Region as subject: Africa Language: English Journal: West Afr J Med Year: 2022 Document Type: Article Affiliation country: Nigeria

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: International databases Database: MEDLINE Main subject: Acute Kidney Injury / COVID-19 / ChAdOx1 nCoV-19 Type of study: Case report / Observational study / Prognostic study Topics: Vaccines Limits: Female / Humans / Middle aged Country/Region as subject: Africa Language: English Journal: West Afr J Med Year: 2022 Document Type: Article Affiliation country: Nigeria